Table 2.

Multivariable-adjusted hazard ratios predicting progression of chronic kidney disease

Models	First renal endpoint (390 vs. 1697)		Sustained renal endpoint (172 vs. 1351)
	Hazard ratio	P value	Hazard ratio	P value
Single-biomarker models
Baseline eGFR	0.71 (0.61 to 0.84)	<0.0001	0.38 (0.29 to 0.52)	<0.0001
UAE	1.29 (1.13 to 1.47)	0.0002	1.19 (0.97 to 1.45)	0.096
CKD273	1.29 (1.15 to 1.44)	<0.0001	1.18 (1.00 to 1.40)	0.050
Two-biomarker models
Baseline eGFR	0.70 (0.60 to 0.83)	<0.0001	0.37 (0.27 to 0.50)	<0.0001
UAE	1.31 (1.14 to 1.50)	<0.0001	1.25 (1.03 to 1.53)	0.027
Baseline eGFR	0.71 (0.61 to 0.83)	<0.0001	0.38 (0.28 to 0.51)	<0.0001
CKD273	1.30 (1.16 to 1.45)	<0.0001	1.21 (1.03 to 1.43)	0.020
Three-biomarker model
Baseline eGFR	0.50 (0.60 to 0.82)	<0.0001	0.37 (0.27 to 0.50)	<0.0001
UAE	1.27 (1.11 to 1.46)	0.0004	1.23 (1.01 to 1.51)	0.043
CKD273	1.28 (1.14 to 1.43)	<0.0001	1.20 (1.02 to 1.42)	0.031

CKD273, urinary proteomic biomarker; eGFR, estimated glomerular filtration rate derived from serum creatinine by the Chronic Kidney Disease Epidemiology Collaboration formula; UAE, urinary albumin excretion rate. Hazard ratios express the increase in risk associated with a 1-SD increase in the baseline biomarkers: 13.1 ml/min per 1.73 m² for estimated glomerular filtration rate, 1.00 for urinary albumin excretion rate, and 0.41 for CKD273. Associations were stratified by center and accounted for sex, age, mean arterial pressure, and prevalence of diabetes at baseline. Five hundred sixty-four participants had only 1 eGFR follow-up measurement and were not included in the analysis of sustained incidence.